English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduExposure in the womb to a drug used to prevent miscarriage appears to raise the offspring’s cancer risk decades later, especially for colorectal and prostate cancers, researchers have found. They will present the results of their new study Tuesday at ENDO 2021, the Endocrine Society’s annual meeting.
Tag: ENDO 2021
High readmission rate found for adults with type 1 diabetes hospitalized for diabetic ketoacidosis
One in five adults with type 1 diabetes who require in-hospital treatment of the life-threatening condition diabetic ketoacidosis has an unplanned repeat hospital visit within a month and is twice as likely to die during the second hospitalization, a new study finds. The results, which will be presented at ENDO 2021, the Endocrine Society’s annual meeting, also identified several factors that increased the readmission risk for these patients.
COVID-19 can cause atypical thyroid inflammation
Some patients with moderate to severe COVID-19 disease seem to experience inflammation of the thyroid gland that is different from thyroid inflammation caused by other viruses, according to a study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
Genetic evidence suggests men can develop PCOS-like condition
New genetic research suggests men can develop characteristics of polycystic ovary syndrome (PCOS)—a common metabolic and reproductive disorder that affects women. The study was presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
Tubeless automated insulin delivery system improves blood glucose outcomes
People with type 1 diabetes can improve their blood sugar control while reducing time with low blood sugar, or hypoglycemia, using Insulet Corporation’s Omnipod 5 Automated Insulin Delivery System compared to their standard insulin therapy. Results from an industry-sponsored study of the latest Omnipod, the first tubeless, wearable insulin pump, will be presented at ENDO 2021, the Endocrine Society’s annual meeting.
First targeted therapy for children with achondroplasia shows persistent height gain for up to two years
Children with achondroplasia, the most common form of disproportionate short stature, grow taller with trends in improved body proportions after two years of daily vosoritide treatment, a new study analysis finds. Results of the industry-sponsored study will be presented at ENDO 2021, the Endocrine Society’s annual meeting.
Combination thyroid hormone therapies treat hypothyroidism as well as levothyroxine
Treatment of hypothyroidism, which results from an underactive thyroid gland, should be individualized and consideration should be given to alternatives to the first-line therapy, including desiccated thyroid extract and combination therapy to replace the body’s two main thyroid hormones, thyroxine (T4) and triiodothyronine (T3). Results of their new randomized clinical study are being presented at ENDO 2021, the Endocrine Society’s annual meeting.
U.S. children from Spanish-speaking households experience higher rate of obesity than those from English-speaking families
Nearly one in five U.S. children and teenagers has obesity, and statistics show a higher prevalence of obesity in certain ethnicities, such as Hispanics and Blacks. Now results of a study being presented at ENDO 2021, the Endocrine Society’s annual meeting, suggest that Spanish as a family’s primary language is a predictor of childhood obesity, regardless of ethnicity.
“Hunger hormone” ghrelin affects monetary decision making
Higher levels of the stomach-derived hormone ghrelin, which stimulates appetite, predict a greater preference for smaller immediate monetary rewards over larger delayed financial rewards, a new study finds. The study results will be presented at ENDO 2021, the Endocrine Society’s annual meeting.
Semaglutide reduces excess body fat in people with obesity
In adults with obesity or overweight, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide leads to reduced excess body fat and increased lean body mass, according to an industry-sponsored study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
Supplements may protect those with low vitamin D levels from severe COVID-19
Patients with low vitamin D levels who are hospitalized for COVID-19 may have a lower risk of dying or requiring mechanical ventilation if they receive vitamin D supplementation of at least 1,000 units weekly, according to a study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
Children, teens with type 1 diabetes had better glucose control during COVID-19 lockdown
Blood glucose levels improved among children and teens with type 1 diabetes during the first 12 weeks of COVID-19 lockdown in the United Kingdom, according to a study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
New treatment shows promise in preventing heart failure after heart attack
A study in mice finds treatment with a molecule called MCB-613 repairs heart tissue after a severe heart attack, preventing damage that can lead to heart failure. The findings are being presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
Night owls with gestational diabetes may face higher risk of pregnancy complications
Among women who develop diabetes during pregnancy, night owls have a higher risk of complications for mother and baby than early birds do, according to a study whose results will be presented at ENDO 2021, the Endocrine Society’s annual meeting.
Many endocrine patients, providers want to continue telehealth after pandemic
Two-thirds of patients with chronic endocrine health problems who need close monitoring say they would like to continue with telemedicine follow-up visits after the COVID-19 pandemic ends, according to a survey that will be presented virtually at ENDO 2021, the Endocrine Society’s annual meeting. Three-quarters of providers also said they want to continue with telehealth after the pandemic.
Study finds oral testosterone therapy undecanoate is effective, with no liver toxicity
An industry-supported study of an oral testosterone replacement therapy (TRT), testosterone undecanoate (TU, brand name Jatenzo) finds it is an effective, long-term treatment for men with low testosterone levels, with no evidence of liver toxicity. The findings are being presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
Osteoporosis drug prescribing often does not follow guidelines
Less than one in 10 commercially insured patients in the United States who broke a hip, a major complication of osteoporosis, receive any osteoporosis medical treatment within two calendar quarters of their fracture, according to a study whose results will be presented at ENDO 2021, the Endocrine Society’s annual meeting.
Nearly one-third of older thyroid patients take medications that interfere with thyroid function tests
Nearly one-third of adults age 65 and older who take thyroid hormone also take medications that are known to interfere with thyroid function tests, according to a study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
Propylparaben exposure during pregnancy, breastfeeding may reduce protection against breast cancer
Low doses of propylparaben—an estrogen-like chemical used as a preservative in personal care products and foods—can alter pregnancy-related changes in the breast in ways that may reduce the normal protection against breast cancer that pregnancy hormones convey, according to a new study being published in the Endocrine Society’s journal Endocrinology.
Virtual ENDO 2021 press conferences to highlight emerging COVID-19 research
Researchers will explore how diabetes, obesity and other endocrine conditions impact the course of the COVID-19 pandemic during the Endocrine Society’s ENDO 2021 virtual news conferences March 22-23.
Media registration open for ENDO 2021
Members of the media can now register to cover the latest advances in hormone health and science at ENDO 2021, the Endocrine Society’s virtual annual meeting being held March 20-23, 2021 in a state-of-the-art digital platform. The virtual meeting will mirror an in-person ENDO with top-flight educational programming and networking opportunities.